ACE and angioedema: Angioedema is a well-recognized risk of angiotensin-converting enzyme (ACE) inhibitors.28 The chemical structure of brodifacoum, however, does not appear to be similar to that class of medications and there is no evidence to suggest that it functionally interacts with ACE receptors29 and it is not otherwise known to inhibit the metabolism of ACE.